Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KIT | P10721 | 1/20 | 0.34 |
| ▸ | MAPK14 | Q16539 | 2/20 | 0.34 |
| ▸ | MAPK13 | O15264 | 1/20 | 0.34 |
| ▸ | MAPK12 | P53778 | 1/20 | 0.34 |
| ▸ | MAPK11 | Q15759 | 1/20 | 0.34 |
| ▸ | CNR1 | P21554 | 1/20 | 0.33 |
| ▸ | ACHE | P22303 | 1/20 | 0.33 |
| ▸ | CNR2 | P34972 | 1/20 | 0.33 |
| ▸ | METAP2 | P50579 | 1/20 | 0.32 |
| ▸ | GRIA1 | P42261 | 1/20 | 0.32 |
| ▸ | LCK | P06239 | 1/20 | 0.31 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.31 |
| ▸ | ACVR2A | P27037 | 1/20 | 0.31 |
| ▸ | TGFBR2 | P37173 | 1/20 | 0.31 |
| ▸ | PTGER1 | P34995 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2280858 | 0.89 | CNR1 (0.35) | KITCNR1ACHECNR2MAPK1 | |
| SCHEMBL2274094 | 0.87 | CNR1 (0.36) | KITCNR1ACHECNR2MAPK1 | |
| SCHEMBL12373961 | 0.86 | PIK3CA (0.37) | CNR1ACHECNR2GRIA1MAPK1 | |
| SCHEMBL2279834 | 0.84 | L3MBTL1 (0.47) | CNR1ACHECNR2 | |
| SCHEMBL3268491 | 0.83 | CASR (0.37) | CNR1ACHECNR2PTGER1 | |
| SCHEMBL17146107 | 0.83 | MAPK1 (0.33) | KITMAPK14MAPK13MAPK12MAPK11 | |
| SCHEMBL13749233 | 0.83 | MAPK1 (0.33) | KITMAPK14MAPK13MAPK12MAPK11 | |
| SCHEMBL16025418 | 0.83 | LRRK2 (0.39) | — | |
| SCHEMBL12374209 | 0.81 | MAPK13 (0.38) | KITMAPK14MAPK13MAPK12MAPK11 | |
| SCHEMBL2468163 | 0.81 | MERTK (0.34) | MAPK14MAPK13MAPK12MAPK11CNR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2260031-B1 | COMPOUNDS THAT ARE ERK INHIBITORS | MERCK SHARP & DOHME (US) | 2015-10-07 | — | — | EP | disclosed |
| US-8716483-B2 | Compounds that are ERK inhibitors | MERCK SHARP & DOHME CORP. (US) | 2014-05-06 | — | — | US | disclosed |
| US-20110189192-A1 | NOVEL COMPOUNDS THAT ARE ERK INHIBITORS | MERCK SHARP & DOHME LLC | 2011-08-04 | — | — | US | disclosed |
| EP-2260031-A1 | COMPOUNDS THAT ARE ERK INHIBITORS | Schering Corporation (US) | 2010-12-15 | — | — | EP | disclosed |
| WO-2009105500-A1 | COMPOUNDS THAT ARE ERK INHIBITORS | SCHERING CORPORATION (US) | 2009-08-27 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110189192-A1 | NOVEL COMPOUNDS THAT ARE ERK INHIBITORS | MAPK1, MAPK4, MAPK10 | KIT 1015/4885MAPK14 26/4885MAPK13 37/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.